Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women

Chinese Medical Journal

Volumn 120, Issue 22, 2007, Pages 2017-2021

  Dai, Yi ^a   Shen, Lin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bone mineral density; Matrix metalloproteinase; Osteoporosis; Osteoprotegerin; Postmenopausal

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCIUM; GELATINASE A; OSTEOPROTEGERIN; PHOSPHORUS;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHINA; CLINICAL INDICATOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL;

EID: 36949036218     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200711020-00015     Document Type: Article

References (34)

1. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-137.
2. Namkung-Matthai H, Appleyard R, Jansen J, Hao LJ, Maastricht S, Swain M, et al. Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. Bone 2001; 28: 80-86.
3. Bauss F, Wagner M, Hothorn LH. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002; 29: 990-998.
4. Kalu DN, Liu CC, Hardin RR, Hollis BW. The aged rat model of ovarian hormone deficiency bone loss. Endocrinology 1989; 124: 7-16.
5. Sims NA, Morris HA, Moore RJ, Durbridge TC. Increased bone resorption precedes increased bone formation in the ovariectomized rat. Calcif Tissue Int 1996; 59: 121-127.
6. Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest 1999; 103: 1409-1418.
7. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luethy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
8. Yasuda HN, Shima N, Nakagawa S, Mochizuki K, Yano N, Fujise Y, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-1337.
9. Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997; 204: 35-46.
10. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176.
11. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko E, Roux ER. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179.
12. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253: 395-400.
13. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 2003; 278: 11888-11896.
14. Birkedal-Hansen EL. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993; 64: 474-484.
15. Rifas L, Fausto A, Scott MJ, Avioli LV, Welgus HG. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis. Endocrinology 1994; 134: 213-221.
16. Vaes G. Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation and mode of action of osteoclasts. Clin Orthop 1988; 231: 239-271.
17. Chambers TJ, Fuller K. Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 1985; 76: 155-165.
18. Holliday LS, Welgus HG, Fliszar CJ, Veith GM, Jeffrey JJ, Gluck SL. Initiation of osteoclast bone resorption by interstitial collagenase. J Biol Chem 1997; 272: 22053-22058.
19. Hill PA, Murphy G, Docherty AJ, Hembry RM, Millican TA, Reynolds JJ, et al. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 1994; 107: 3055-3064.
20. Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003; 12: 109-125.
21. Westermarck J, Kahari V. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792.
22. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999; 878: 212-227.
23. Liao EY, Wu XP, Deng XG, Huang G, Zhu XP, Long ZF, et al. Age-related bone mineral density, accumulated bone loss rate and prevalence of osteoporosis at multiple skeletal sites in Chinese women. Osteoporos Int 2002; 13: 669-676.
24. Liao EY, Wu XP, Luo XH, Zhang H, Dai RC, Huang G, et al. Establishment and evaluation of bone mineral density reference databases appropriate for diagnosis and evaluation of osteoporosis in Chinese women. J Bone Miner Metab 2003; 21: 184-192.
25. Wu XP, Liao EY, Zhang H, Shan PF, Cao XZ, Liu SP. Establishment of BMD reference plots and determination of peak BMD at multiple skeletal regions in mainland Chinese women and the diagnosis of osteoporosis. Osteoporos Int 2004; 15: 71-79.
26. Garnero P, Somay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fracture in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-1536.
27. Bucay NI, Sarosi CR, Dunstan S, Morony J, Tarpley C, Capparelli S, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268.
28. Mizuno AN, Amizuka K, Irie A, Murakami N, Fujise T, Kanno Y, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615.
29. Pacifici R. Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043-1051.
30. Perry HM 3rd, Bernard M, Horowitz M, Miller DK, Fleming S, Baker MZ, et al. The effect of aging on bone mineral metabolism and bone mass in native American women. J Am Geriatr Soc 1998; 46: 1418-1422.
31. Nakaoka D, Sugimoto T, Kaji H, Kanzawa M, Yano S, Yamauchi M, et al. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women. Osteoporos Int 2001; 12: 548-554.
32. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998; 139: 1338-1345.
33. Ichinose Y, Migita K, Nakashima T, Kawakami A, Aoyagi T, Eguchi K. Effects of bisphosphonate on the release of MMP-2 from cultured human osteoblasts. Tohoku J Exp Med 2000; 192: 111-118.
34. Filanti C, Dickson GR, Di Martino D, Ulivi V, Sanguineti C, Romano P, et al. The expression of metalloproteinase-2, -9, and -14 and of tissue inhibitors-1 and -2 is developmentally modulated during osteogenesis in vitro, the mature osteoblastic phenotype expressing metalloproteinase-14. J Bone Miner Res 2000; 15: 2154-2168.